Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Sam Gidding Articles

PlayMaking premature CHD history

Making premature CHD history

Dr Samuel Gidding discusses how treating children with FH early can make premature CHD history

read more »
Posted on 1 June 2015 | Posted by Sam Gidding | Posted in Hot topics, Videos, 17th International Symposium on Atherosclerosis 2015
PlayHow to identify children with FH

How to identify children with FH

Dr Samuel Gidding discusses how to identify children with FH

read more »
Posted on 1 June 2015 | Posted by Sam Gidding | Posted in Hot topics, Videos, 17th International Symposium on Atherosclerosis 2015
PlayISA 2015: EAS Consensus Panel publishes Position Statement on Paediatric Familial Hypercholesterolaemia

ISA 2015: EAS Consensus Panel publishes Position Statement on Paediatric Familial Hypercholesterolaemia

The European Atherosclerosis Society (EAS) Consensus Panel has today published a new position paper aiming to raise awareness of the urgent need to identify and treat children with familial hypercholesterolaemia (FH) early. The EAS Consensus Panel position paper also provides clinical guidance for the diagnosis…

read more »
Posted on 25 May 2015 | Posted by Albert Wiegman, Sam Gidding | Posted in News, Videos, 17th International Symposium on Atherosclerosis 2015
PlayUnmet needs in children with FH

Unmet needs in children with FH

Identification and treatment to reduce low density lipoprotein cholesterol (LDL-C) of children with familial hypercholesterolaemia (FH) is vital to reduce the risk of cardiovascular death in early adulthood. FH is the most common genetic disorder in the world. Parents and healthcare professionals need to be…

read more »
Posted on 30 October 2014 | Posted by Sam Gidding | Posted in News, Article Archive, Videos

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.
Educational Partners and Supporters
AstraZeneca AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation
Lib Therapeutics Novartis Sanofi
© Copyright 2024 PCSK9 Forum. All rights reserved